Back to top
more

Charles River Laboratories International (CRL)

(Real Time Quote from BATS)

$226.73 USD

226.73
268,285

-12.70 (-5.30%)

Updated Apr 25, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CRL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 277 234 241 228 238
Receivables 780 752 643 618 514
Notes Receivable 0 0 0 0 0
Inventories 380 256 199 186 161
Other Current Assets 171 197 191 169 109
Total Current Assets 1,609 1,439 1,274 1,201 1,021
Net Property & Equipment 1,640 1,466 1,291 1,124 1,044
Investments & Advances 244 312 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 40 41 40 38 45
Intangibles 3,959 3,805 2,792 1,875 1,616
Deposits & Other Assets 309 148 1,334 1,074 826
Total Assets 8,195 7,603 7,024 5,491 4,693
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 169 206 198 122 112
Current Portion Long-Term Debt 0 0 3 50 39
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 441 417 475 357 298
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 445 469 357 310 262
Total Current Liabilities 1,055 1,092 1,033 840 710
Mortgages 0 0 0 0 0
Deferred Taxes/Income 191 216 240 217 167
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,647 2,708 2,664 1,930 1,850
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 223 175 243 205 183
Minority Interest (Liabilities) 57 42 53 26 29
Total Liabilities 4,593 4,622 4,485 3,373 3,055
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 1,906 1,805 1,718 1,628 1,532
Retained Earnings 1,887 1,433 981 625 280
Other Equity -191 -257 -161 -135 -175
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,602 2,981 2,539 2,118 1,638
Total Liabilities & Shareholder's Equity 8,195 7,603 7,024 5,491 4,693
Total Common Equity 3,602 2,981 2,539 2,118 1,638
Shares Outstanding 51.30 50.90 50.40 49.70 48.90
Book Value Per Share 70.22 58.57 50.38 42.62 33.49

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 277 157 200 202
Receivables NA 780 799 801 788
Notes Receivable NA 0 0 0 0
Inventories NA 380 293 285 263
Other Current Assets NA 171 195 218 196
Total Current Assets NA 1,609 1,444 1,505 1,448
Net Property & Equipment NA 1,640 1,525 1,530 1,494
Investments & Advances NA 244 302 300 294
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 40 34 39 41
Intangibles NA 3,959 3,771 3,846 3,860
Deposits & Other Assets NA 309 155 155 154
Total Assets NA 8,195 7,607 7,772 7,699
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 169 136 140 120
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 441 422 412 397
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 445 435 456 464
Total Current Liabilities NA 1,055 994 1,008 981
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 191 185 207 212
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 2,647 2,514 2,678 2,744
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 173 177 187
Minority Interest (Liabilities) NA 57 40 42 43
Total Liabilities NA 4,593 4,296 4,515 4,586
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,906 1,877 1,850 1,830
Retained Earnings NA 1,887 1,720 1,633 1,536
Other Equity NA -191 -263 -202 -234
Treasury Stock NA 0 24 24 19
Total Shareholder's Equity NA 3,602 3,311 3,258 3,114
Total Liabilities & Shareholder's Equity NA 8,195 7,607 7,772 7,699
Total Common Equity 0 3,602 3,311 3,258 3,114
Shares Outstanding 51.50 51.30 51.30 51.20 51.10
Book Value Per Share 0.00 70.22 64.54 63.62 60.94